Fig. 5From: Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations Distinct spatiotemporal distributions of PTX nanoformulations in GC1 PDOs. A The distributions of PTX nanoformulations in GC1 PDOs as revealed by CLSM at the indicated time points. Blue: DAPI; red: fluorescent-labeled Albu-PTX or Lipo-PTX. Scale bar, 50 μm. B The distributions of PTX nanoformulations in GC1 PDOs as revealed by fluorescence colocalization analysis. Blue: DAPI; red: fluorescent-labeled Albu-PTX or Lipo-PTX. Scale bar, 20 μm. C A series of Z-stack images showing the distributions of PTX nanoformulations in GC1 PDOs. Blue: DAPI; red: fluorescent-labeled Albu-PTX or Lipo-PTX. Scale bar, 30 μmBack to article page